Barclays PLC Has $3.41 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)

Barclays PLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 24.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 230,901 shares of the medical research company’s stock after selling 75,782 shares during the quarter. Barclays PLC owned about 0.18% of NeoGenomics worth $3,405,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. State Street Corp increased its holdings in shares of NeoGenomics by 1.6% during the 3rd quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock valued at $73,139,000 after acquiring an additional 80,449 shares during the last quarter. First Light Asset Management LLC boosted its position in NeoGenomics by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after purchasing an additional 480,396 shares during the period. Dimensional Fund Advisors LP grew its holdings in NeoGenomics by 7.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after purchasing an additional 217,687 shares during the last quarter. American Century Companies Inc. raised its position in shares of NeoGenomics by 5.4% in the second quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after purchasing an additional 167,145 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its stake in shares of NeoGenomics by 67.0% in the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock worth $27,928,000 after buying an additional 759,524 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on NEO shares. Benchmark reiterated a “buy” rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Bank of America lifted their price objective on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Jefferies Financial Group initiated coverage on NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.30.

NeoGenomics Stock Performance

NEO opened at $16.53 on Tuesday. The stock’s 50 day simple moving average is $15.80 and its 200-day simple moving average is $15.29. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The stock has a market cap of $2.12 billion, a PE ratio of -27.10 and a beta of 1.24. NeoGenomics, Inc. has a 1 year low of $12.77 and a 1 year high of $20.94.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.06) EPS. Sell-side analysts forecast that NeoGenomics, Inc. will post -0.16 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.